Pacific Edge (PEB) Investor presentation summary

Executive summary

• Patented, non-invasive Cxbladder urine tests deliver clinical, economic, and patient value, with Triage receiving a 'Grade A' evidence rating from the AUA, the only urine biomarker to do so.

• Draft Local Coverage Determination (LCD) for Triage and Triage Plus expected before September 2026, with final LCD before March 2027; claim-by-claim reimbursement to be sought after draft LCD.

• Global bladder cancer market opportunity estimated at US$10.8 billion, driven by ~7 million hematuria diagnoses annually in the US.

• Cash burn reduced in 2H FY26 to NZ$2.4m/month from NZ$3.3m in 1H FY26 through cost-saving measures; further reductions targeted for FY27.

• Triage Plus confirmed Medicare pricing at US$1,328/test, up from US$760 for Triage, with focus on sales force efficiency and scaling post-coverage.

Capital raising and financial performance

• NZ$24 million equity raise (NZ$18m placement, NZ$6m retail offer) at NZ$0.170/share, a 2.3% discount to last traded price, to strengthen balance sheet and support growth.

• FY26 unaudited operating revenue fell to $11.5m from $21.8m in FY25 due to Medicare non-coverage; net loss increased to $35.7m from $29.9m.

• Cash and cash equivalents at 30 April 2026 were $5.1m; post-offer, available funding expected to be NZ$29.1m.

• Total expenses fell to $49.3m from $54.6m in FY25, with capital conservation initiatives reducing cash burn by 27.7% in 2H FY26.

• APAC revenue and test volumes grew, contributing 19% of 2H26 operating revenue, while US volumes declined due to Medicare issues.

Product and market development

• Cxbladder suite includes Triage, Detect, Triage Plus, Monitor, and Surveillance Plus, targeting both hematuria evaluation and NMIBC surveillance.

• Triage Plus offers improved performance and higher pricing; Surveillance Plus in development, targeting CPT-PLA code submission by December 2026.

• Over 130,000 patients and 5,000 urologists have used Cxbladder; more than 30 publications support its clinical utility.

• Cxbladder can avoid unnecessary cystoscopies, saving >US$500/patient and sparing over 1.5 million US patients from invasive procedures.

• APAC operations trending toward profitability, with expanded adoption in New Zealand, Australia, and Southeast Asia.